The Maastricht guidelines and other innovations

Current Opinion in Gastroenterology

Volumn 13, Issue SUPPL. 1, 1997, Pages 1-7

  Malfertheiner, P ^a   O'Morain, C ^b   Michetti, P ^c,d  

^a OTTO VON GUERICKE UNIVERSITY   (Germany)

^b ADELAIDE AND MEATH HOSPITAL   (Ireland)

^c POLICLINIQUE MÉDICALE UNIVERSITAIRE   (Switzerland)

^d BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; UREASE; VACCINE;

CELLULAR IMMUNITY; GENOME; GRAM NEGATIVE INFECTION; HELICOBACTER PYLORI; HUMAN; NETHERLANDS; PRACTICE GUIDELINE; REVIEW; SYMPOSIUM;

EID: 0030761697     PISSN: 02671379     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (57)

1. Breuer T, Malaty HM, Goodman K, Sudhop T, Graham DY: Treatment regime used in Helicobacter pylori positive ulcer disease; a nationwide comparison of gastroenterologists and family practitioners in the USA. Gut 1996, 39 (suppl 2):A22.
2. Penston JG, Mistry KR: Eradication of Helicobacter pylori in general practice. Aliment Pharmacol Ther 1996, 10:139-145.
3. The European Helicobacter Pylori Study Group Current European concepts in management of Helicobacter pylori infection. The Maastricht Consensus Report. Gut 1997, 41:8-13.
4. Valori RM, Brown CM, Strangeways P: Community dyspepsia workshops reduce dyspepsia drug costs. Gut 1996, 38 (suppl 1):A34.
5. Bell GD, Powell KU, Burridge SM, Bowden AF, Atoyebi W, Bolton GH, Jones PH, Brown C: Rapid eradication of Helicobacter pylori infection. Aliment Pharmacol Ther 1995, 9:41-46.
6. Feldman RA, Deeks JJ, Evans SJ: Multi-laboratory comparison of eight commercially available Helicobacter pylori serology kits. Helicobacter pylori Serology Study Group. Eur J Clin Microbiol Infect Dis 1995, 14:428-433.
7. Peitz U, Labenz J, Tillenburg LB, Baumann M, Borsch G: Validity of a new whole blood test for Helicobacter pylori infection. Gut 1995, 37 (suppl 2):A107.
8. Duggan AE, Knifton A, Logan RPH, Hawkey CJ, Logan RFA: Validation of two new blood tests for Helicobacter pylori. Gut 1995, 37 (suppl 2):A85.
9. Casale V, Stigliano V, Abbolito MR, Fracasso P, Grassi A, Lapenta R: Diagnosis of Helicobacter pylori active infection in symptomatic patients by a new rapid serological test. Gut 1995, 37 (suppl 2):A205.
10. Breslin NP, Flynn S, Balbirnie E, O'Morain C: Validation of an 'Office' serological test for Helicobacter pylori. Gastroenterology 1996, 110:A68.
11. Estève J, Kricker A, Ferlay J, Parkin DM in collaboration with the Steering Committee of The European Network of Cancer Registries: Facts and figures of cancer in the European Community 1993. Lyon: International Agency for Research on Cancer.
12. Heikkinen M, Pikkarainen P, Takala J, Räsänen H, Julkunen R: Etiology of dyspepsia: four hundred unselected consecutive patients in general practice. Scand J Gastroenterol 1995, 30:519-523.
13. Tham TCK, McLaughlin N, Hughes DF, Ferguson M, Crosbie JJ, Madden MM, Nannyak S, O'Connor A: Possible role of Helicobacter pylori serology in reducing endoscopy workload. Postgrad Med J 1994, 70:809-812.
14. Collins JSA, Bamford KB, Sloan JM, Collins BJ, Moorehead RJ, Love AHG et al.: Screening for Helicobacter pylori antibody could reduce endoscopy workload in young dyspeptic patients. Eur J Gastroenterol 1992, 4:991-993.
15. Sobala GM, Crabtree JE, Pentith JA, Rathbone BJ, Shallcross TM, Wyatt JI, Dixon MF, Heatley RV, Axon AT: Screening dyspepsia by serology to Helicobacter pylori. Lancet 1991, 338:94-96.
16. Breslin N, Lee J, Buckley M, O'Morain C: Screening of young dyspeptics - an alternative hypothesis. Ir J Med Sci 1996, 165 (suppl 4): 16.
17. Patel P, Khulusi S, Mendall MA, Lloyd R, Jazrawi R, Maxwell JD et al.: Prospective screening of dyspeptic patients by Helicobacter pylori serology. Lancet 1995, 346:1315-1318.
18. Sonnenberg A: Cost benefit analysis of testing for Helicobacter pylori in dyspeptic patients. Am J Gastroenterol 1996, 91:1773-1777.
19. Briggs AH, Sulpher MJ, Logan RPH, Aldous J, Ramsay ME, Baron JH: Cost-effectiveness of screening for Helicobacter pylori in management of dyspeptic patients under 45 years of age. BMJ 1996, 312:1321-1325.
20. Fendrick AM, Chernew ME, Hirsh RA, Bloom BS: Alternative management strategies for patients with suspected peptic ulcer disease. Ann Int Med 1995, 123:260-268.
21. Buckley M, Xia H, Hyde D, O'Morain C: Cost effective, European approach to Helicobacter pylori eradication. Gut 1995, 37 (suppl 2):A175.
22. Lamouliatte H, Cayla R, Zerbils F, Talbi P, Mégraud F: Triple therapy using proton pump inhibitor, amoxycillin and clarithromycin for Helicobacter pylori eradication. Gut 1995, 37 (suppl 2):A151.
23. Dixon MF, Genta RM, Yardley JH, Correa P: Classification and grading of gastritis. The updated Sydney System. Am J Surg Path 1996, 20:1161-1181.
24. Hopkins RJ, Girardi LS, Turney EA: Relationship between Helicobacter pylori eradication and reduced duodenal and gastric ulcer recurrence [Review]. Gastroenterology 1996, 110:1244-1252.
25. Graham DY, Hepps KS, Ramirez FC, Lew GM, Saeed ZA: Treatment of Helicobacter pylori reduces the rate of rebleeding in peptic ulcer disease. Scand J Gastroenterol 1993, 28:939-942.
26. Labenz J, Börsch G: Role of Helicobacter pylori eradication in the prevention of peptic ulcer bleeding relapse. Digestion 1994, 55:19-23.
27. Rokkas T, Karameris A, Mavrogeorgis A, Rallis E, Giannikos N: Eradication of Helicobacter pylori reduces the possibility of rebleeding in peptic ulcer disease. Gastrointest Endos 1995, 41:1-4.
28. Phull PS, Ryder SD, Halliday D, Price AB, Levi AJ, Jacyna M: The economic and quality of life benefits of Helicobacter pylori eradication in chronic duodenal ulcer disease - a community based study. Postgrad Med J 1995, 71:413-418.
29. Kosunen TU Seppala K, Sarna S, Sipponen P: Diagnostic value of decreasing IgG, IgA and IgM antibody titres after eradication of Helicobacter pylori. Lancet 1992, 339:893-895.
30. Ferrana M, Vianello F, Basso D, Leandro G, DalBo N, Salandin S et al.: Serological tests for diagnosing Helicobacter pylori eradication. Gut 1995. 37 (suppl 2):A195.
31. Uemura N, Mukai T, Okamoto S, Yamaguchi S, Mashiba H, Taniyama K et al.: Helicobacter pylori eradication inhibits the growth of intestinal type of gastric cancer in initial stage. Gastroenterology 1996, 110:A.
32. Lee YT, Chan FKL, Sung JY, Leung VKS, To KF, Yung MF et al.: Prevention of NSAID-induced ulcer by eradication of H. pylori. A prospective randomized study. Gut 1996, 39 (suppl 2):A26.
33. Ng TM, Fock KM, Khor JL, Teo EK, Chia SC: Helicobacter pylori and NSAIDs in bleeding gastric ulcer. Gut 1996, 39 (suppl 2):A2(3A;25).
34. Talley NJ: A critique of therapeutic trials in Helicobacter pylori positive functional dyspepsia. Gastroenterology 1994, 11:74-83.
35. McCarthy C, Patchett S, Collins RM, Beattie S, Keane C, O'Morain C: Long-term prospective study of Helicobacter pylori in nonulcer dyspepsia. Dig Dis Sci 1995, 40:114-119.
36. Kuipers EJ, Lundell L, Klinkenberg-Knol EC, Havu N, Festen HPM, Liedman B, Lamers CB, Jansen JB, Dalenback J, Snel P et al.: Atrophic gastritis and Helicobacter pylori infection in patients with reflux esophagitis treated with omeprazole or fundoplication. N Eng J Med 1996, 334:1018-1022.
37. Lundell L, Havu N, Andersson A, Miettinen P, Myrvold HE, Pedersen SA, Thor K and the Nordic GERD Study Group: Gastritis development and acid suppression therapy revisited: results of a randomised clinical study with long-term follow-up. Washington DC American Gastroenterological society 97th Annual meeting 1997.
38. Unge P: Review of Helicobacter pylori eradication regimens. Scand J Gastroenterol 1996, 31 (suppl 215):74-81.
39. Bazzoli F, Zagari RM, Fossi S, Pozzato P, Alampi G, Simoni P et al.: Short-term low-dose triple therapy for the eradication of Helicobacter pylori Eur J Gastroenterol Hepatol 1994, 6:773-777.
40. Bell GD, Powell KU, Burridge SM, Bowden AF, Atoyebi W, Bolton GH, Jones PH, Brown C: Rapid eradication of Helicobacter pylori infection. Aliment Pharmacol Ther 1995, 9:41-46.
41. Moayyedi P, Sahay P, Tompkins DS, Axon ATR: Efficacy and optimum dose of omeprazole in a new 1-week triple therapy regimen to eradicate Helicobacter pylori. Eur J Gastroenterol Hepatol 1995, 7:835-840.
42. Labenz J, Stolte M, Rühl GH, Becker T, Tulenburg B, Sollböhmer M, Borsch G: One-week low-dose triple therapy for the eradication of Helicobacter pylori infection. Eur J Gastroenterol Hepatol 1995, 7:9-11.
43. Japp BH, Norby A: Low dose, short-term triple therapy for cure of Helicobacter pylori infection and healing of peptic ulcers. Am J Gastroenterol 1995, 90:943-945.
44. Lind T, Veldhuyzen van Zanten S, Unge P, Spiller R, Bayerdörffer E, O'Morain C et al.: Eradication of Helicobacter pylori using one-week triple therapies combining omeprazole with two antimicrobials: the MACH 1 study. Helicobacter 1996, 1:138-144.
45. Misiewicz JJ, Harris AW, Bardhan KD, Levi S, Langworthy H: One week low-dose triple therapy for eradication of H. pylori: a large multicentre, randomised trial. Gastroenterology 1996, 110:A198.
46. Labenz J, Tillenburg B, Weismüller J, Lûtke A, Stolte M: Efficacy and tolerability of a one-week triple therapy consisting of pantoprazole, clarithromycin and amoxycillin for cure of Helicobacter pylori in patients with duodenal ulcer. Aliment Pharmacol Ther 1997, in press.
47. Labenz J, Peitz U, Tillenburg B, Becker T, Börsch G, Stolte M: Short-term triple therapy with pantoprazole, clarithromycin and metronidazole for eradication of Helicobacter pylori. Leber Magen Darm 1995, 25:122-127.
48. Kreiss C, Buclin T, Cosma M, Corthésy-Theulaz I, Michetti P: Safety of oral immunization with recombinant urease in patients with Helicobacter pylori infection. Lancet 1996, 347:1630-1631.
49. Thomas JE, Austin S, Dale A, McClean P, Harding M, Coward WA, Weaver LT: Protection by human milk IgA against Helicobacter pylori infection in infancy (Letter). Lancet 1993, 342:121.
50. Corthésy-Theulaz I, Ferrero RL: Vaccines. Curr Opin Gastr 1997, 12 (suppl 1):41-44.
51. Mohammadi M, Czinn S, Redline R, Nedrud J: Adoptive transfer of Helicobacter-specific Th1 or Th2 cells exacerbates Helicobacter-associated gastritis, but only Th2 cells reduce the magnitude of infection [Abstract]. Gut 1996, 39 (suppl 2):A45. This elegant study describes adoptive transfer of spleen cells or of characterized T helper subsets from immunized/challenged mice to H. felis-infected recipients. Transfer of spleen cells and of a Th2 cell line (but not cells from infected mice or Th1 cell lines) led to a significant reduction in the bacterial load. These results indicate a prominent role for Th2 cells in gastric protective immunity.
52. Ferrera RL, Thiberge JM, Kansau I, Wuscher N, Huerre M, Labigne A: The GroES homolog of Helicobacter pylori confers protective immunity against mucosal infection in mice. Proc Natl Acad Sci U S A 1995, 92:6499-6503.
53. Mohammadi M, Czinn S, Redline R, Nedrud J: Helicobacter-specific cell-mediated immune responses display a predominant Th1 phenotype and promote a delayed-type hypersensitivity response in the stomach of mice. J Immunol 1996, 156:4729-4738. This article reports the presence of a Th1 cellular immune response in mice following infection with H. felis or oral immunization. This response correlated with the degree of inflammation which could be reduced by treatment with anti-IFN-gamma treatment. This treatment allowed the authors to evidence a Th2 immune response present only in immunized animals. These observations are compatible with a local delayed-type hypersensitivity in the stomach in response to infection and/or immunization.
54. Radcliff FJ, Ramsay AJ, Lee A: Failure of immunization against Helicofaacter infection in IL-4 deficient mice: evidence for a Th2 immune response as the basis for protective immunity [Abstract]. Gastroenterology 1996, 110:A997.
55. Saldinger PF, Porta N, Waanders GA, Launois P, Louis JA, Michetti P, Blum AL, Corthésy-Theulaz I: Therapeutic immunization of Helicobacter infected BALB/c mice induces a switch of the cellular response from Th1 to Th2 [Abstract]. Gastroenterology 1997, 112:A1080. Proliferation and cytokine production by splenic CD4+ T cells was followed in mice during successive therapeutic immunization with H. pylori urease B subunit. A progressive decrease in the bacterial load was observed in association with a switch from a Th1 to a Th2 immune response, as demonstrated by the production of IFN-gamma and IL-4, respectively.
56. Cuenca R, Blanchard TG, Czinn SJ, Nedrud JG, Monath TP, Lee CK, Redline RW: Therapeutic immunization against Helicobacter mustelae in naturally infected ferrets. Gastroenterology 1996, 110:1770-1775. This is the first report of successful therapeutic immunization in a natural model of Helicobacter infection. Seven out of 23 H. mustelae-infected ferrets were cured by oral immunization with H. pylori urease versus none of eleven controls (P=0.04). Furthermore, in animals in which bacterial eradication was not observed, the degree of inflammation was reduced.
57. Michetti P, Kreiss C, Kotloff KL, Porta N, Blanco JL, Bachmann D, Saldinger PF, Corthésy-Theulaz I, Losonsky G, Nichols R et al.: Oral immunization of H pylori infected adults with recombinant urease and LT adjuvant [Abstract]. Gastroenterology 1997, 112:A1042. This study reports the first attempt to induce an immune response against H. pylori in humans. Helicobacter pylori-infected volunteers received four weekly doses of recombinant H. pylori urease given with E. coli LT. This short immunization schedule was proven to be safe and was not associated with delayed-type reaction in the gastric mucosa. IgA immune response occurred to urease and to LT.